Irradiated Products

Blood Banking and Transfusion Medicine

Volumn , Issue , 2007, Pages 397-409

  Luban, Naomi L C ^a,b,c,d,e   Wong, Edward C C ^d,f  

^a Center for Cancer and Blood Disorders   (United States)

^b Laboratory Medicine and Pathology   (United States)

^c Transfusion Medicine The Edward J Miller Donor Center   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^f GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960151629     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-443-06981-9.50033-8     Document Type: Chapter

References (108)

1. von Fliedner V, Higby DJ, Kim U Graft-versus-host reaction following blood product transfusion. Am J Med 1972, 72:951-961.
2. Anderson KC, Weinstein HJ Transfusion-associated graft-versus-host disease. N Engl J Med 1990, 323:315-321.
3. Webb IJ, Anderson KC Transfusion-associated graft-versus-host disease. Scientific Basis of Transfusion Medicine 2000, 420-425. WB Saunders, Philadelphia. K.C. Anderson, P.M. Ness (Eds.).
4. Linden JV, Pisciotto PT Transfusion-associated graft-versus-host disease and blood irradiation. Transfus Med Rev 1992, 6:116-123.
5. Yasuura K, Okamoto H, Matsuura A Transfusion-associated graft-versus-host disease with transfusion practice in cardiac surgery. J Cardiovasc Surg (Torino) 2000, 41:377-380.
6. Serious Hazards of Transfusion. Available at. Accessed March 29, 2006. http://www.shotuk.org.
7. Kleinman S, Chan P, Robillard P Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev 2003, 17:120-162.
8. Ferrera JM, Krenger W Graft-versus-host disease: the influence of type 1 and type 2 T cell cytokines. Transfus Med Rev 1998, 12:1-17.
9. McMilan KD, Johnson RL HLA-homozygosity and the risk of related-donor transfusion-associated graft-versus-host disease. Transfus Med Rev 1993, 7:37-41.
10. Petz LD, Calhoun L, Yam P, et al. Transfusion-associated graft-versus-host disease in immunocompetent patients: report of a fatal case associated with transfusion of blood from a second-degree relative, and a survey of predisposing factors. Transfusion 1993, 33:742-750.
11. Worrall NK, Lazenby WD, Misko TP, et al. Modulation of in vivo alloreactivity by inhibition of inducible nitric oxide synthetase. J Exp Med 1995, 181:63-70.
12. Fast LD, DiLeone G, Edson CM, et al. PEN110 treatment functionally inactivates the PBMNCs present in RBC units: comparison to the effects of exposure to gamma irradiation. Transfusion 2002, 42:1318-1325.
13. Nishimura M, Uchida S, Mitsunaga S, et al. Characterization of T-cell clones derived from peripheral blood lymphocytes of a patient with transfusion-associated graft-versus-host disease: FAS-mediated killing by CD4+ and CD8+ cytotoxic T-cell clones and tumor necrosis factor beta production by CD4+ T-cell clones. Blood 1997, 89:1440-1445.
14. Ammann AJ Hypothesis: absence of graft-versus-host disease in AIDS is a consequence of HIV-1 infection of CD4+ T cells. J Acquir Immune Defic Syndr 1993, 6:1224-1227.
15. Klein C, Fraitag S, Foulon E, et al. Moderate and transient transfusion-associated cutaneous graft versus host disease in a child infected by human immunodeficiency virus. Am J Med 1996, 101:445-446.
16. Lee TH, Reed W, Mangawang-Montalvo L, et al. Donor WBCs can persist and transiently mediate immunologic function in a murine transfusion model: effects of irradiation, storage, and histocompatibil-ity. Transfusion 2001, 41:637-642.
17. Lee TH, Donegan E, Slichter S, Busch MP Transient increase in circulating donor leukocytes after allogeneic transfusions in immuno-competent recipients compatible with donor cell proliferation. Blood 1996, 85:1207-1214.
18. Lee TH, Paglieroni T, Ohto H, et al. Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: frequent long term microchimerism in severe trauma patients. Blood 1999, 93:3127-3139.
19. Lee TH, Paglieroni T, Utter GH, et al. High-level long-term white blood cell microchimerism after transfusion of leukoreduced blood components to patients resuscitated after severe traumatic injury. Transfusion 2005, 45:1280-1290.
20. Utter GH, Owings JT, Lee TH, et al. Microchimerism in transfused trauma patients is associated with diminished donor-specific lymphocyte response. J Trauma 2005, 58:925-931. discussion 931-932.
21. Wang-Rodriguez J, Fry E, Fiebig E, et al. Immune response to blood transfusion in very-low-birthweight infants. Transfusion 2000, 40:25-34.
22. Vietor HE, Hallensleben E, van Bree SP, et al. Survival of donor cells 25 years after intrauterine transfusion. Blood 2000, 95:2709-2714.
23. Reed WF, Lee TH, Trachlenberg E, et al. Detection of microchime-rism by PCR as a function of amplification strategy. Transfusion 2001, 41:39-44.
24. Nelson J, Furst D, Maloney S, et al. Microchimerism and HLA compatible relationships of pregnancy in scleroderma. Lancet 1998, 351:559-562.
25. Arlett CM, Smith JB, Jimenez SA Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 1998, 333:1186-1191.
26. Evans PC, Lambert N, Maloney S, et al. Long-term fetal microchime-rism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma. Blood 1999, 93:2033-2037.
27. Daya S, Gunby J, Clark DA Intravenous immunoglobulin therapy for recurrent spontaneous abortion: a meta-analysis. Am J Reprod Immunol 1998, 39:69-76.
28. Brubaker DB Immunopathogenic mechanisms of posttransfusion graft versus host disease. Proc Soc Exp Biol Med 1993, 202:122-147.
29. Blundell EL, Pamphilon DH, Anderson NA, et al. Transfusion-associated graft-versus-host disease, monoclonal gammopathy and PCR. Br J Haematol 1992, 82:622-623.
30. Capon SM, DePond WD, Tyan DB, et al. Transfusion associated graft-versus-host disease in an immunocompetent patient. Ann Intern Med 1991, 114:1025-1026.
31. Drobyski W, Thibodeau S, Truitt RL, et al. Third-party-mediated graft rejection and graft-versus-host disease after T-cell-depleted bone marrow transplantation, as demonstrated by hypervariable DNA probes and HLA-DR polymorphism. Blood 1989, 74:2285-2294.
32. Kunstmann E, Bocker T, Roewer L, et al. Diagnosis of transfusion-associated graft-versus-host disease by genetic fingerprinting and polymerase chain reaction. Transfusion 1992, 32:766-770.
33. Depalma L, Bahrami KR, Kapur S, et al. Amplified fragment length polymorphism analysis in the evaluation of posttransfusion graft versus host disease. J Thorac Cardiovasc Surg 1994, 108:182-184.
34. Wang L, Juji T, Tokunaga K, et al. Polymorphic microsatellite markers for the diagnosis of graft-versus-host disease. N Engl J Med 1994, 330:398-401.
35. Friedman DF, Kwittken P, Cizman B, et al. DNA-based HLA typing of nonhematopoietic tissue used to select the marrow transplant donor for successful treatment of transfusion-associated graft-versus-host disease. Clin Diagn Lab Immunol 1994, 1:590-596.
36. Higgins MJ, Blackall DP Transfusion-associated graft-versus-host disease: a serious residual risk of blood transfusion. Curr Hematol Reports 2005, 4:470-476.
37. Kanter MH Transfusion-associated graft-versus-host disease: do transfusions from second-degree relatives pose a greater risk than those from first-degree relatives?. Transfusion 1992, 32:323-327.
38. Luban NL, DePalma L Transfusion-associated graft-versus-host disease in the neonate-expanding the spectrum of disease [editorial]. Transfusion 1996, 36:101-103.
39. Ohto H, Anderson KC Post-transfusion graft-versus-host disease in Japanese newborns. Transfusion 1996, 36:117-123.
40. Van Royen-Kerkhof A, Wulffraat NM, Kamphuis SS, et al. Nonlethal transfusion associated graft-versus-host disease in a severe combined immunodeficient patient. Bone Marrow Transplant 2003, 32:1027-1030.
41. Juji T, Nishimura M, Tadokoro K Treatment of posttransfusion graft-versus-host disease. Vox Sang 2000, 78(Suppl 2):277-279.
42. Hutchinson K, Kopko PM, Muto KN, et al. Early diagnosis and successful treatment of a patient with transfusion-associated GVHD in autologous peripheral blood progenitor cell transplantation. Transfusion 2002, 42:1567-1572.
43. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999, 285:412-415.
44. Gorlin JB, Mintz PD Transfusion-associated graft-vs-host-disease. Transfusion Therapy: Clinical Principles and Practice 2005, 579-591. American Association of Blood Banks, Bethesda, Md. P.D. Mintz (Ed.).
45. Fearon TC, Luban NL Practical dosimetric aspects of blood and blood product irradiation. Transfusion 1986, 26:457-459.
46. Korngold R Biology of graft-versus-host disease. Am J Pediatr Hema-tol Oncol 1993, 15:18-37.
47. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Available at. Accessed March 29, 2006. http://www.fda.gov/cber/guidelines.htm.
48. Suda BA, Leitman SF, Davey RJ Characteristics of red cells irradiated and subsequently frozen for long term storage. Transfusion 1993, 33:389-392.
49. Miraglia CC, Anderson G, Mintz PD Effect of freezing on the in vivo recovery of irradiated red cells. Transfusion 1994, 34:775-778.
50. Crowley JP, Skrabut EM, Valeri CR Immunocompetent lymphocytes in previously frozen washed red cells. Vox Sang 1974, 26:513-517.
51. Akahoshi M, Takanashi M, Masuda M, et al. A case of transfusion-associated graft-versus-host disease not prevented by white cell-reduction filters. Transfusion 1992, 32:169-172.
52. Heim MU, Munker R, Sauer H, et al. Graft versus host Krankheit: GVH mit letalem Ausgang nach der Gabe von gefilterten Erythrozy-tenkonzentraten [Graft versus host disease with fatal outcome after administration of filtered erythrocyte concentrates]. Beitr Infusion-sther 1992, 30:178-181.
53. Hayashi H, Nishiuchi T, Tamura H, et al. Transfusion associated graft-versus-host disease caused by leukocyte filtered stored blood. Anesthesiology 1993, 79:1419-1421.
54. Anderson KC Leukodepleted cellular blood components for prevention of transfusion-associated graft-versus-host disease. Transfus Sci 1995, 16:265-268.
55. Ramirez AM, Woodfield DG, Scott R, et al. High potassium levels in stored irradiated blood. Transfusion 1987, 27:444-445.
56. Rivet C, Baxter A, Rock G Potassium levels in irradiated blood [letter]. Transfusion 1989, 29:185.
57. Swann ID, Williamson LM Potassium loss from leukodepleted red cells following gamma-irradiation. Vox Sang 1996, 70:117-118.
58. Strauss RG Routine washing of irradiated red cells before transfusion seems unwarranted. Transfusion 1990, 30:675-677.
59. Luban NL, Strauss RG, Hume HA Commentary on the safety of red cells preserved in extended-storage media for neonatal transfusion. Transfusion 1991, 31:229-235.
60. Weiskopf RB, Schnapp S, Rouine-Rapp K, et al. Extracellular potassium concentrations in red blood cell suspensions after irradiation and washing. Transfusion 2005, 45:1295-1301.
61. Wielding JU, Vehmeyer K, Dittman J, et al. Contamination of fresh-frozen plasma with viable white cells and proliferable stem cells [letter]. Transfusion 1994, 34:185-186.
62. Bernvill SS, Abdulatiff M, Al-Sedairy S, et al. Fresh frozen plasma contains viable progenitor cells-should we irradiate [letter]?. Vox Sang 1994, 67:405.
63. Benson K, Marks AR, Marshall MJ, et al. Fatal graft-versus-host disease associated with transfusions of HLA-matched, HLA-homozygous platelets from unrelated donors. Transfusion 1994, 34:432-437.
64. Grishaber JE, Birney SM, Strauss RG Potential for host transfusion-associated graft-versus-host disease due to apheresis platelets matched for HLA class I antigens. Transfusion 1993, 33:910-914.
65. Chang H, Voralia M, Bali M, et al. Irreversible loss of donor blood leucocyte activation may explain a paucity of transfusion-associated graft-versus-host disease from stored blood. Br J Haematol 2000, 111:146-156.
66. Davey RJ, McCoy NC, Yu M, et al. The effect of pre-storage irradiation on post-transfusion red cell survival. Transfusion 1992, 32:525-528.
67. Mintz PD, Anderson G Effect of gamma irradiation on the in vivo recovery of stored red blood cells. Ann Clin Lab Sci 1993, 23:216-220.
68. Moroff G, Holme S, Heaton A, et al. Effect of gamma irradiation on viability of AS-1 red cells [abstract]. Transfusion 1992, 32(Suppl):70S.
69. Janatpour K, Denning L, Nelson K, et al. Comparison of x-ray vs. gamma irradiation of CPDA-1 red cells. Vox Sang 2005, 89:215-219.
70. Moroff G, Holme S, AuBuchon JP, et al. Viability and in vitro properties of AS-1 red cells after gamma irradiation. Transfusion 1999, 39:128-134.
71. Cicha I, Suzuki Y, Tateishi N, et al. Gamma-ray-irradiated red blood cells stored in mannitol-adenine-phosphate medium: rheological evaluation and susceptibility to oxidative stress. Vox Sang 2000, 79:75-82.
72. Leitner GC, Neuhauser M, Weigel G, et al. Altered intracellular purine nucleotides in gamma-irradiated red blood cell concentrates. Vox Sang 2001, 81:113-118.
73. Hirayama J, Abe H, Azuma H, et al. Leakage of potassium from red blood cells following gamma ray irradiation in the presence of dipyridamole, trolox, human plasma, or mannitol. Biol Pharm Bull 2005, 28:1318-1320.
74. Moroff G, George VM, Siegl AM, et al. The influence of irradiation on stored platelets. Transfusion 1986, 26:453-456.
75. Espersen GT, Ernst E, Christiansen OB, et al. Irradiated blood platelet concentrates stored for five days: evaluation by in vitro tests. Vox Sang 1988, 55:218-221.
76. Duguid JK, Carr R, Jenkins JA, et al. Clinical evaluation of the effects of storage time and irradiation on transfused platelets. Vox Sang 1991, 60:151-154.
77. Read EJ, Kodis C, Carter CS, et al. Viability of platelets following storage in the irradiated state. A paired-controlled study. Transfusion 1988, 28:446-450.
78. Rock G, Adams GA, Labow RS The effects of irradiation on platelet function. Transfusion 1988, 28:451-455.
79. Sweeney JD, Holme S, Moroff G Storage of apheresis platelets after gamma irradiation. Transfusion 1994, 34:779-783.
80. Seghatchian MJ, Stivala JF Effect of 25 Gy gamma irradiation on storage stability of three types of platelet concentrates: a comparative analysis with paired controls and random preparation. Transfus Sci 1995, 16:121-129.
81. Bessos H, Atkinson A, Murphy WG, et al. A comparison of in vitro storage markers between gamma-irradiated and non-irradiated apher-esis platelet concentrates. Transfus Sci 1995, 16:131-134.
82. Anderson KC, Goodnough LT, Sayers M, et al. Variation in blood component irradiation practice: implications for prevention of transfusion-associated graft-versus-host disease. Blood 1991, 77:2096-2102.
83. Sprent J, Anderson RE, Miller JF Radiosensitivity of T and B lymphocytes. II. Effect of irradiation on response of T cells to alloantigens. Eur J Immunol 1974, 4:204-210.
84. Valerius NH, Johansen KS, Nielsen OS, et al. Effect of in vitro x-irradiation on lymphocyte and granulocyte function. Scand J Hematol 1981, 27:9-18.
85. Rosen NR, Weidner JG, Bold HD, et al. Prevention of transfusion-associated graft-versus-host disease: selection of an adequate dose of gamma irradiation. Transfusion 1993, 33:125-127.
86. Pelszynski MM, Moroff G, Luban NL, et al. Effect of gamma-irradiation of red blood cell units on T-cell inactivation as assessed by limiting dilution analysis: implications for preventing transfusion-associated graft-versus-host disease. Blood 1994, 83:1683-1689.
87. Luban NL, Drothler D, Moroff G, et al. Irradiation of platelet components: inhibition of lymphocyte proliferation assessed by limiting dilution analysis. Transfusion 2000, 40:348-352.
88. Quinones RR, Gutierrez RH, Dinndorf PA, et al. Extended cycle elutriation to adjust T-cell content in HLA-disparate bone marrow transplantation. Blood 1993, 82:307-317.
89. Moroff G, Luban NL The irradiation of blood and blood components to prevent graft-versus-host disease: technical issues and guidelines. Transfus Med Rev 1997, 11:15-26.
90. Masterson ME, Febo R Pre-transfusion blood irradiation: clinical rationale and dosimetric considerations. Med Phys 1992, 19:649-657.
91. Leitman SF Dose, dosimetry and quality improvements of irradiated blood components [editorial]. Transfusion 1993, 33:447-449.
92. Perkins JT, Papoulias SA The effect of loading conditions on dose distri bution within a blood irradiator [abstract]. Transfusion 1994, 34:75S.
93. Moroff G, Luban NLC, Wolf L, et al. Dosimetry measurements after gamma irradiation with cesium-137 and linear acceleration sources [abstract]. Transfusion 1993, 33:52S.
94. Luban NL, Fearon T, Leitman SF, et al. Absorption of gamma irradiation in simulated blood components using cesium irradiators [abstract]. Transfusion 1995, 35:63S.
95. Goes EG, Covas DT, Haddad R, et al. Quality control system for blood irradiation using a teletherapy unit. Vox Sang 2004, 86:105-110.
96. Kutcher GJ, Coia L, Gillin M, et al. Comprehensive QA for radiation oncology: report of AAPM Radiation Therapy Committee Task Group 40. Med Phys 1994, 21:581-618.
97. Nath R, Biggs PJ, Bova FJ, et al. AAPM code of practice for radiotherapy accelerators: report of AAPM Radiation Therapy Task Group 45. Med Phys 1994, 21:1093-1121.
98. Fearon T, Criss VR, Luban NLC Blood irradiator dosimetry with BANG polymer gels. Transfusion 2005, 45:1658-1662.
99. Leitman SF, Silberstein L, Fairman RM, et al. Use of a radiation-sensitive film label in the quality control of irradiated blood components [abstract]. Transfusion 1992, 32:4S.
100. Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in human platelet concentrates using a novel psoralen and long wavelength UV light. Transfusion 1997, 37:423-435.
101. Corash L, Lin L Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant 2004, 33:1-7.
102. Hei DJ, Grass J, Lin L, et al. Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light. Transfusion 1999, 39:239-248.
103. Grass JA, Hei DJ, Metchette K, et al. Inactivation of leukocytes in platelet concentrates by psoralen plus UVA. Blood 1998, 91:2180-2188.
104. Grass JA, Wafa T, Reames A, et al. Prevention of transfusion- associated graft-versus-host disease by photochemical treatment. Blood 1999, 93:3140-3147.
105. Fast LD The effect of exposing murine splenocytes to UVB light, psoralen plus UVA light, or gamma-irradiation on in vitro and in vivo immune responses. Transfusion 2003, 43:576-583.
106. Grass J, Delmonte J, Wages D, et al. Prevention of transfusion-associated graft vs. host disease (TA-GVHD) in immunocompromised mice by photochemical treatment (PCT) of donor T cells. Blood 1997, 90(Suppl 1):207A.
107. Technical Manual 2005, American Association of Blood Banks, Bethesda, Md. M.E. Brechner (Ed.).
108. Dzik WH Leukoreduced blood components: laboratory and clinical aspects. Rossi's Principles of Transfusion Medicine 2002, 270-287. Lippincott, Philadelphia. 3rd ed. T.L. Slonim, W.H. Dzik, E.L. Snyder, C.P. Stowell, R.G. Strauss (Eds.).